The GNPTG Knockout Jurkat Polyclonal Cells are a CRISPR/Cas9-edited human T-lymphocyte population featuring targeted disruption of the GNPTG gene. As a polyclonal pool, these cells represent a genetically heterogeneous loss-of-function model, enabling studies that circumvent clonal selection bias while maintaining robust functional readouts relevant to the gamma subunit of N-acetylglucosamine-1-phosphotransferase.
Jurkat cells are an immortalized T-lymphoblastoid line originally established from the peripheral blood of an acute T-cell leukemia patient. Widely adopted as a model for T-cell receptor signaling and oncology research, these suspension-adapted cells are readily transfectable, making them an ideal host for CRISPR/Cas9-mediated genome editing. Their lymphoid origin provides a physiologically relevant cellular environment for exploring lysosomal trafficking and hydrolase sorting in immune cells.
GNPTG encodes the gamma subunit of GlcNAc-1-phosphotransferase, which forms a hexameric complex with the alpha and beta subunits encoded by GNPTAB. This enzyme catalyzes the first step in mannose 6-phosphate (M6P) modification, adding phosphorylated N-acetylglucosamine to N-linked glycans of nascent lysosomal hydrolases. The M6P tag is recognized by CI-MPR and CD-MPR receptors, which mediate clathrin-dependent sorting from the trans-Golgi network to endolysosomal compartments. Disruption of GNPTG abolishes proper M6P formation, causing misrouting and secretion of critical enzymes including cathepsins, glycosidases, and sulfatases. Upstream, TFEB directly transactivates GNPTG as part of the coordinated lysosomal expression and regulation (CLEAR) network, integrating signals from mTORC1 and nutrient status. Consequently, loss of GNPTG decouples lysosomal biogenesis from enzyme trafficking, leading to profound lysosomal dysfunction.
In Jurkat T cells, GNPTG knockout recapitulates fundamental aspects of mucolipidosis III gamma, a lysosomal storage disorder resulting from defective M6P tagging. This model allows researchers to investigate how compromised lysosomal enzyme delivery alters T-cell activation thresholds, degranulation dynamics, and antigen presentation capacity??processes that rely on proper lysosomal function. The polyclonal nature of the population mirrors the allelic heterogeneity found in patient variants, offering a more representative system than single clones for drug responsiveness studies. Additionally, it enables dissection of non-classical roles of lysosomes in lymphocyte signaling and metabolic adaptation.
Applications span detailed mechanistic studies of M6P pathway regulation, high-content phenotypic screening for small molecules that rescue lysosomal enzyme sorting, and functional interrogation of lysosomal dynamics using advanced imaging and flow cytometry. Representative assays include Western blotting and RT-qPCR for expression analysis, immunofluorescence to monitor hydrolase localization, LAMP1/CD107a surface staining to assess lysosomal exocytosis, and enzymatic activity measurements for cathepsin D. Lysosomal pH indicators and substrate accumulation assays further characterize dysfunction. For customized solutions and technical inquiries, please contact Ascent Research.
